Clinical Trial Update: Trial Of Erlotinib With Or Without PF-3512676 In Advanced Non Small Cell Lung Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating erlotinib with or without PF-3512676 for advanced non-small cell lung cancer has completed enrollment; the update does not provide tria…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• ERLOTINIB (Erlotinib)
• PF-3512676

Snippet

Sponsor: Pfizer | Conditions: Carcinoma, Non-Small-Cell Lung | Phase 2 | Status: COMPLETED